Celltrion Healthcare is continuing to make the case for switching from intravenous to subcutaneous formulations of infliximab, with the latest data drop suggesting there may be benefits beyond ...

This activity is part of an ongoing CME/CE initiative to provide information on labeling changes reported by the FDA. Activities of this nature will be posted on Medscape on a weekly basis. June 3, ...

When it comes to biologics like Rituxan and Remicade, which are intravenous infusions, decision making can be impacted by cost. Dr Fendrick asked the panelists what might hypothetically happen if cost ...

LAS VEGAS, Nev., October 23, 2006 -- Patients with ulcerative colitis (UC) treated with REMICADE® (infliximab) had an approximate 50 percent reduction in mean number of hospitalizations per year ...

Generic drugs generally cost 80 percent less than brand-name drugs, so hopes were high when a law enacted in 2010 paved the way for competition among the highest-priced drugs of all, known as ...

Please provide your email address to receive an email when new articles are posted on . Patients with inflammatory bowel disease who received home infusions of Remicade had higher rates of ...

Celltrion is hoping patients make the jump from Johnson & Johnson and Merck blockbuster Remicade to its biosimilar, Remsima--and now it has real-world data to support a switch. In an independent Phase ...

NEW YORK (Reuters) - Crohn's disease patients taking Johnson & Johnson's Remicade either alone or with azathioprine experienced steroid-free remission in significantly greater numbers than those ...

As with other drugs, Remicade (infliximab) can cause side effects, such as infusion reactions. If you are not able to tolerate side effects of Remicade, talk with your doctor or pharmacist. Remicade ...